Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116) Meeting Abstract
| Authors: | Rosen, E.; Silverman, I. M.; Fontana, E.; Lee, E. K.; Spigel, D. R.; Højgaard, M.; Lheureux, S.; Mettu, N. B.; Carneiro, B. A.; Carter, L.; Plummer, E. R.; Schonhoft, J. D.; Ulanet, D.; Manley, P.; Reis-Filho, J. S.; Xu, Y.; Rimkunas, V.; Koehler, M.; Yap, T. A. |
| Abstract Title: | Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300975 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.3082 |
| Notes: | Meeting Abstract: 3082 -- Meeting also held virtually -- Source: Wos |
